Actively Recruiting
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Led by Yonsei University · Updated on 2019-12-13
3000
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Urological cancers such as prostate, renal cell, bladder, and ureter cancers are increasing in the Korean population due to aging and lifestyle changes. Researchers are studying the use of circulating tumor DNA found in plasma and urine to help diagnose these cancers, monitor their progression, and evaluate treatment responses. The study also aims to build a large database of circulating tumor DNA profiles for these cancers in Korean patients and develop an optimized testing platform. The study involves patients diagnosed with one of the four urological cancers who have undergone surgery specific to their cancer type, such as prostatectomy, nephrectomy, cystectomy, or ureterectomy. Blood and urine samples will be collected to analyze circulating tumor DNA, which will be compared with genetic mutations found in the removed tumor tissue. The study will monitor these patients for up to 10 years after surgery to observe correlations between circulating tumor DNA and early diagnosis or prognosis. Participants will provide consent to use their medical and genetic information for the study and will be followed regularly to collect plasma and urine samples. Researchers will assess the relationship between circulating tumor DNA and tumor genetics shortly after surgery and over the long term. This observational study does not involve treatment interventions but focuses on collecting data to improve personalized medicine approaches for urological cancers.
CONDITIONS
Brief Title
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with urological malignancies (prostate, renal cell, bladder, or ureter cancer)
- Patients who have undergone surgery for urological malignancies at Severance Hospital from December 2019 to November 2029
- Patients who agree to allow use of their medical and human source information
- Patients who agree to participate in this study
You will not qualify if you...
- Patients who do not agree to participate in this study
- Vulnerable individuals likely to be coerced or unable to make decisions independently
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 2 weeks after surgery
Participants undergo surgery for urological malignancies, and genetic mutations in circulating tumor DNA and primary tumor tissue samples are analyzed.
1 to 2 visits depending on sample collection timing
Duration - Up to 10 years after surgery
Participants are observed to assess the correlation between circulating tumor DNA and early diagnosis and prognosis in urological malignancies over time.
Periodic visits as needed for up to 10 years
Trial Site Locations
Total: 1 location
1
Department of Urology, Urological Science Institute, Yonsei University, Colleage of Medicine
Seoul, South Korea, 03722
Actively Recruiting
Research Team
W
Won Sik Ham
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here